Sibille M, Vital Durand D
Unité de Recherche Thérapeutique and Rhône-Poulenc-Santé, Centre Hospitalier Lyon Sud, France.
Eur J Clin Pharmacol. 1990;39(5):475-9. doi: 10.1007/BF00280939.
The aim of laboratory screening in Phase I is to exclude subjects with subclinical illness, who might be at increased risk in the study, and who might also adversely influence interpretation of the results. A new method for laboratory screening, based on Bayesian probability theory, is proposed, which consists of: 1. Drawing up a list of diseases to be excluded. 2. Defining for each disease, the maximum acceptable risk that an included subject could be affected by it. 3. Identifying one test for each disease. 4. Using a contingency table to calculate the specificity of the test and integrating the estimated prevalence of the disease from epidemiological data. 5. Applying the percentage obtained by the calculation of specificity to the previously determined distribution of values in the volunteer population to identify the threshold value for inclusion. Use of this deductive method in screening volunteers for Phase I trials affords increased security of selection, while reducing the number of non-pertinent exclusions because of laboratory findings.
I期实验室筛查的目的是排除患有亚临床疾病的受试者,这些受试者在研究中可能风险增加,并且可能对结果的解释产生不利影响。本文提出了一种基于贝叶斯概率理论的实验室筛查新方法,该方法包括:1. 列出要排除的疾病清单。2. 为每种疾病定义纳入受试者可能受其影响的最大可接受风险。3. 为每种疾病确定一项检测。4. 使用列联表计算检测的特异性,并结合流行病学数据估计疾病的患病率。5. 将通过计算特异性获得的百分比应用于志愿者人群中先前确定的值分布,以确定纳入阈值。在I期试验志愿者筛查中使用这种演绎方法可提高选择的安全性,同时减少因实验室检查结果导致的无关排除数量。